HIV prevention shot achieved a 96% success rate in clinical trials, but accessibility and regulatory hurdles remain a ...

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

Over 23,850 people living with HIV in Tanzania have been diagnosed with advanced stages of the disease, according to the ...

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus ...

HOOKIPA Pharma Inc. has announced the completion of participant enrollment in a Phase 1b clinical trial for HB-500, a next-generation therapeutic vaccine aimed at treating HIV. The trial ...

Peer-led interventions for improving HIV prevention among Latino MSM exist, but research is needed before they can be fully ...

(RTTNews) - HOOKIPA Pharma Inc. (HOOK), a clinical-stage biopharmaceutical company, announced on Thursday that enrollment has been completed in its Phase 1b clinical trial evaluating HB-500 for ...

The Phase 1b clinical trial (NCT06430905) is evaluating the safety and tolerability, reactogenicity, and immunogenicity to repeated doses of HB-500 in participants with HIV on suppressive ...